Clofarabine ± Fludarabine with Once Daily i. v

Slides:



Advertisements
Similar presentations
Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation  Li Mei Poon, Amir Hamdi, Rima.
Advertisements

Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease.
Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation  Li Mei Poon, Amir Hamdi, Rima.
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction  Muzaffar H. Qazilbash, Ali Imran.
Ulas D. Bayraktar, Denái R. Milton, Elizabeth J
The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk.
Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.
Muzaffar H. Qazilbash, MD, Peter Thall, PhD, Patricia S
High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid.
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Outcome of Patients with Multiple Myeloma by Ethnicity in the Setting of Autologous Stem Cell Transplant  Koji Sasaki, MD, Qaiser Bashir, MD, Nina Shah,
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
Moderate Renal Function Impairment Does Not Affect Outcomes of Reduced-Intensity Conditioning with Fludarabine and Melphalan for Allogeneic Hematopoietic.
T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL) 
Clinical Outcomes of Multiple Myeloma Patients with TP53 Gene Deletion after Autologous Stem Cell Transplantation: The MD Anderson Cancer Center Experience 
Safety and Efficacy of Haploidentical Stem Cell Transplantation for Advanced Chronic Myeloid Leukemia  Kehinde Adekola, MD, Antonio di Stasi, MD, Roberto.
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes 
Long-Term Follow-Up of Patients Who Experienced Graft Failure Postallogeneic Progenitor Cell Transplantation. Results of a Single Institution Analysis 
Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.
Synergistic Cytotoxicity of Sorafenib with Busulfan and Nucleoside Analogs in Human FMS-like Tyrosine Kinase 3 Internal Tandem Duplications–Positive Acute.
Outcomes of Patients with Myeloid Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation from Matched Unrelated Donors Compared.
Quantifying the Survival Benefit for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Acute Myelogenous Leukemia  Paul M. Armistead, Marcos.
Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma  Gaurav C. Parikh, Ali Imran Amjad, Rima.
Study Design of an Expanded Access Protocol of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients Years of Age with Secondary Acute.
Hepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral Agents  Andreas Kyvernitakis,
Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease.
Significance of Persistent Cytogenetic Abnormalities on Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission  Betul Oran, Uday.
Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-,
Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia  Reinhold Munker, Ruta Brazauskas, Hai Lin Wang, Marcos.
Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen–
Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3- ITD Allelic Ratio in FLT3-ITD–Positive Acute Myelogenous Leukemia 
Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes  Koen Van Besien,
Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia  Fleur M. Aung,
Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning.
Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia:
Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients.
The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation  Rohtesh S. Mehta, Antonio Di Stasi, Borje S.
A Phase III Study of Infliximab and Corticosteroids for the Initial Treatment of Acute Graft-versus-Host Disease  Daniel R. Couriel, Rima Saliba, Marcos.
Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma  Koji Sasaki, Gary Lu, Rima M. Saliba,
Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing.
Outcome of Patients with Multiple Myeloma with t(4;14) after Autologous Hematopoietic Stem Cell Transplantation  Koji Sasaki, MD, Rima Saliba, PhD, Gary.
Biology of Blood and Marrow Transplantation
Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic.
Haploidentical Transplantation for Advanced Hematologic Malignancies Using Melphalan-Based Conditioning – Mature Results from a Single Center  Sai Ravi.
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas 
Dose Intensification of Busulfan in the Preparative Regimen Is Associated with Improved Outcomes: A Phase I/II Controlled, Randomized Study  Simrit Parmar,
Resolved Hepatitis B Virus Infection Is Not Associated with Worse Outcome after Allogeneic Hematopoietic Stem Cell Transplantation  Carlos A. Ramos, Rima.
Myeloablative Reduced-Toxicity i. v
Nonmyeloablative Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients 60 Years or Older  Vikas Gupta, Andrew Daly,
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic.
Cytogenetics and Blast Count Determine Transplant Outcomes in Advanced AML  Uday R. Popat, MD, Rima Saliba, PhD, Betul Oran, MD, Julianne Chen, BS, Amin.
Comparison of High-Dose Gemcitabine, Busulfan and Melphalan (GEM/BU/MEL) and BEAM in Concurrent Patient Cohorts with Mature T-CELL NON-Hodgkin's Lymphoma.
Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation  Stefan O. Ciurea, Marcos de Lima, Sergio Giralt, Rima Saliba, Carlos.
Lymphocyte Recovery Predicts Outcomes in Cord Blood and T Cell–Depleted Haploidentical Stem Cell Transplantation  Stefan O. Ciurea, Victor Mulanovich,
Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia Patients  Mithun Vinod Shah, Rima M.
Outcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan- Based Conditioning  Jonathan E. Brammer, Issa Khouri, Sameh Gaballa,
Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem.
Muzaffar H. Qazilbash, Rima M
Dose Intensification of Busulfan in the Preparative Regimen is Associated with Improved Survival: A Phase I/II Controlled, Randomized Study  Simrit Parmar,
Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.
Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation  Stefan O. Ciurea,
Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome 
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
Megadose CD34+ Cell Grafts Improve Recovery of T Cell Engraftment but not B Cell Immunity in Patients with Severe Combined Immunodeficiency Disease Undergoing.
Mary Eapen  Biology of Blood and Marrow Transplantation 
Daniel Couriel, Chitra Hosing, Rima Saliba, Elizabeth J
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin.
Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS:
Once Daily i. v. Busulfan and Fludarabine (i. v
Results of Allogeneic Double Umbilical Cord Blood Transplantation for Relapsed and Refractory Hodgkin Lymphoma  Philip A. Thompson, MBBS, FRACP, FRCPA,
Presentation transcript:

Clofarabine ± Fludarabine with Once Daily i. v Clofarabine ± Fludarabine with Once Daily i.v. Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS  Borje S. Andersson, Benigno C. Valdez, Marcos de Lima, Xuemei Wang, Peter F. Thall, Laura L. Worth, Uday Popat, Timothy Madden, Chitra Hosing, Amin Alousi, Gabriela Rondon, Partow Kebriaei, Elizabeth J. Shpall, Roy B. Jones, Richard E. Champlin  Biology of Blood and Marrow Transplantation  Volume 17, Issue 6, Pages 893-900 (June 2011) DOI: 10.1016/j.bbmt.2010.09.022 Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 The synergistic cytotoxicity of 0.015 μM Clo and 0.6 μM Flu is shown by an increase to 22% and 42% cells with sub-G1 DNA content and TUNEL-positive, respectively (Figure 1A and B). These effects of the [Clo + Flu] combination were further enhanced when 20 μg/mL Bu was added into the mixture and resulted in 40% cells in sub-G1 and 65% cells positive to TUNEL assay (Figure 1A and B), suggesting an increase in the proportion of cells undergoing apoptosis. Biology of Blood and Marrow Transplantation 2011 17, 893-900DOI: (10.1016/j.bbmt.2010.09.022) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Kaplan-Meier estimates for the overall (red line) and progression-free (blue line) survival of all 51 patients treated on the Clo ± Flu with i.v. Bu protocol. Biology of Blood and Marrow Transplantation 2011 17, 893-900DOI: (10.1016/j.bbmt.2010.09.022) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Kaplan-Meier estimates for overall survival of the 42 AML/MDS patients. The low clofarabine group is Arms I and II (the lower doses of 10 or 20 mg/m2/day clofarabine together with fludarabine at 30 and 20 mg/m2/day, respectively, blue line), and the high clofarabine group refers to Arms III and IV (30 or 40 mg/m2/day clofarabine with fludarabine at 10 mg/m2/day and 0 mg/m2/day, respectively, red line). The numbers within the brackets refer to the number of events in the respective groups (5/12 in the low Clo group and 10/30 in the high Clo group). Biology of Blood and Marrow Transplantation 2011 17, 893-900DOI: (10.1016/j.bbmt.2010.09.022) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Kaplan-Meier estimates for progression-free survival in the 42 AML/MDS patients. The low clofarabine group is Arms I and II (the lower doses of 10 or 20 mg/m2/day clofarabine together with fludarabine at 30 and 20 mg/m2/day, respectively, blue line), and the high clofarabine group refers to Arms III and IV (30 or 40 mg/m2/day clofarabine with fludarabine at 10 mg/m2/day and 0 mg/m2/day, respectively, red line). The numbers within the brackets refer to the number of events in the respective groups. Biology of Blood and Marrow Transplantation 2011 17, 893-900DOI: (10.1016/j.bbmt.2010.09.022) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions